These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013 [TBL] [Abstract][Full Text] [Related]
8. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509 [TBL] [Abstract][Full Text] [Related]
10. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab. Wan MJ; Hooper PL; Sheidow TG Can J Ophthalmol; 2010 Aug; 45(4):375-80. PubMed ID: 20648087 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156 [TBL] [Abstract][Full Text] [Related]
13. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A Retina; 2006; 26(9):988-93. PubMed ID: 17151484 [TBL] [Abstract][Full Text] [Related]
14. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Lazic R; Gabric N Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776 [TBL] [Abstract][Full Text] [Related]
15. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Bakri SJ; Couch SM; McCannel CA; Edwards AO Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278 [TBL] [Abstract][Full Text] [Related]
16. Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency. Mataix J; Palacios E; Carmen DM; Garcia-Pous M; Navea A Retina; 2010 Sep; 30(8):1190-6. PubMed ID: 20539256 [TBL] [Abstract][Full Text] [Related]